Purpose: NRG Oncology RTOG 9704 was the first adjuvant trial to validate the prognostic value of postresection CA19-9 levels for survival in patients with pancreatic carcinoma. The data resulting from this study also provide information about predictors of recurrence that may be used to tailor individualized management in this disease setting. This secondary analysis assessed the prognostic value of postresection CA19-9 and surgical margin status (SMS) in predicting patterns of disease recurrence.
Methods And Materials: This multicenter cooperative trial included participants who were enrolled as patients at oncology treatment sites in the United States and Canada. The study included 451 patients analyzable for SMS, of whom 385 were eligible for postresection CA19-9 analysis. Postresection CA19-9 was analyzed at cut points of 90, 180, and continuously. Patterns of disease recurrence included local/regional recurrence (LRR) and distant failure (DF). Multivariable analyses included treatment, tumor size, and nodal status. To adjust for multiple comparisons, a value of ≤ .01 was considered statistically significant and > .01 to ≤ .05 to be a trend.
Results: For CA19-9, 132 (34%) patients were Lewis antigen-negative (no CA19-9 expression), 200 (52%) had levels <90, and 220 (57%) had levels <180. A total of 188 patients (42%) had negative margins, 152 (34%) positive, and 111 (25%) unknown. On univariate analysis, CA19-9 cut at 90 was associated with increases in LRR (trend) and DF. Results were similar at the 180 cut point. SMS was not associated with an increase in LRR on univariate or multivariate analyses. On multivariable analysis, CA19-9 ≥ 90 was associated with increased LRR and DF. Results were similar at the 180 cut point.
Conclusions: In this prospective evaluation, postresection CA19-9 was a significant predictor of both LRR and DF, whereas SMS was not. These findings support consideration of adjuvant radiation therapy dose intensification in patients with elevated postresection CA19-9.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000159 | PMC |
| http://dx.doi.org/10.1016/j.adro.2018.01.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which is Best?
Ann Surg
December 2024
Department of Surgery, Stanford University, Stanford, CA.
Objective: To examine the optimal method of assessing response to neoadjuvant therapy (NAT) in operable pancreatic ductal adenocarcinoma (PDAC) patients.
Summary Of Background Data: PDAC response to NAT is measured with biochemical, radiographic and pathologic parameters, which can often be discordant with each other.
Methods: PDAC patients undergoing resection after NAT at a single institution were retrospectively analyzed.
A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable and borderline resectable pancreatic cancer.
Surgery
October 2024
Department of Surgery, Osaka International Cancer Institute, Japan.
Article Synopsis
- Identifying patients who won't benefit from invasive pancreatic cancer surgery is important to preserve quality of life, especially after neoadjuvant therapy for resectable cases.
- The study analyzed 609 patients, categorizing them into poor-prognosis (those with rapid recurrence or no surgery) and good-prognosis groups (those without recurrence or longer recurrence intervals).
- Key findings showed that elevated levels of carbohydrate antigen 19-9 (specifically >200 U/mL) after treatment were strongly linked to poor survival rates, indicating that patients with such levels should avoid radical surgery due to low chances of benefit.
Tumor Size Combined With CA-19 Level Improves Prediction of Survival of Patients With Pancreatic Adenocarcinoma Undergoing Perioperative Chemotherapy and Resection.
Am Surg
June 2024
Department of General Surgery, Cleveland Clinic, Cleveland, OH, USA.
Article Synopsis
- Five-year survival rates for pancreatic adenocarcinoma are below 20%, and the role of carbohydrate antigen 19-9 (CA19-9) in predicting outcomes post-surgery is unclear.
- A study of 109 patients analyzed the relationship between CA19-9 levels, tumor size, and survival outcomes after surgery, distinguishing between short (less than 1 year) and prolonged (more than 2 years) survival.
- Results showed that higher CA19-9 levels were linked to shorter survival, particularly for small (≤2 cm) and large (>4 cm) tumors, suggesting that combined CA19-9 levels and tumor size can improve predictions of post-surgery outcomes.
Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which Patients Are Suited for Additional Adjuvant Chemoradiation Therapy: From a Prospective Randomized Study.
Int J Radiat Oncol Biol Phys
September 2023
National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan; Department of Radiation Oncology, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan; Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan. Electronic address:
Purpose: The predictive value of carbohydrate antigen 19-9 (CA19-9) for adjuvant chemo(radiation) therapy of resected pancreatic adenocarcinoma (PDAC) is undefined.
Methods And Materials: We analyzed CA19-9 levels in patients with resected PDAC in a prospective randomized trial of adjuvant chemotherapy with or without additional chemoradiation therapy (CRT). Patients with postoperative CA19-9 ≤92.
Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma.
Ann Surg
March 2023
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Objective: To characterize associations between carbohydrate antigen 19-9 (CA19-9) dynamics during neoadjuvant therapy (NT) and survival for patients with pancreatic ductal adenocarcinoma (PDAC).
Background: Although normalization of CA19-9 during NT is associated with improved outcomes following PDAC resection, we hypothesize that CA19-9 dynamics during NT can improve prognostication.
Methods: Characteristics for patients with PDAC undergoing NT (July 2011-October 2018) with ≥3 CA19-9 results (bilirubin<2mg/dL) were collected and grouped by CA19-9 dynamics.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!